Last updated: March 21, 2024
Sponsor: Koya Medical, Inc.
Overall Status: Completed
Phase
N/A
Condition
Varicose Veins
Stasis Dermatitis
Deep Vein Thrombosis
Treatment
Cross over Device (PCD or Dayspring - alternate to first group)
Clinical Study ID
NCT05507346
KCT 009 (TEAYS)
Ages 18-100 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Males and females ≥ 18 years of age
- Capable and willing to sign the informed consent and deemed capable of following thestudy protocol
- Subjects must have a diagnosis of primary or secondary unilateral or bilateral lowerextremity edema or lower extremity phlebolymphedema from chronic venous insufficiency
Exclusion
Exclusion Criteria:
- Individuals with a history or presence of a systemic disorder or condition that couldplace the subject at increased risk from sequential compression therapy
- Inability or unwillingness to participate in all aspects of study protocol and/orinability to provide informed consent
- Subjects with exam results that would prevent safe and effective use of the studydevice (cellulitis, open-wounds, healing-wounds, etc.)
- Subjects must not have any diagnosed cognitive or physical impairment that wouldinterfere with use of the device
- Individuals who present with Ankle-brachial Index (ABI) screening score < 0.8 and > 1.30, indicating the possibility of Peripheral Arterial disease (PAD)
- Diagnosis of lipedema
- Diagnosis of active or recurrent cancer (< 3 months since completion of chemotherapy,radiation therapy or primary surgery for the cancer)
- Diagnosis of acute infection (in the last four weeks)
- Diagnosis of acute thrombophlebitis (in last 6 months)
- Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months
- Diagnosis of pulmonary edema
- Diagnosis of congestive heart failure (uncontrolled/uncompensated)
- Diagnosis of chronic kidney disease with acute renal failure
- Diagnosis of epilepsy
- Subjects with poorly controlled asthma
- Any condition where increased venous and lymphatic return is undesirable
- Women who are pregnant, planning a pregnancy or nursing at study entry
- Participation in any clinical trial of an investigational substance or device duringthe past 30 days
Study Design
Total Participants: 121
Treatment Group(s): 1
Primary Treatment: Cross over Device (PCD or Dayspring - alternate to first group)
Phase:
Study Start date:
September 06, 2022
Estimated Completion Date:
January 09, 2024
Study Description
Connect with a study center
Stanley G Rockson
Oakland, California 94607
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.